Dec. 15 at 5:53 AM
ALK-Abelló – Denmark's next pharma highflyer?
You are unlikely to have heard of
$AKBLF, but it's a hidden champion that could yet get a lot more attention over the years to come.
The company commands a 35% global market share in immunotherapies for allergies. Just 1% of its 500m strong target market is using these therapies yet, which leaves massive potential for growth.
ALK-Abelló's share price is down 40% over the past two years. Is now the right time to add this company to your watchlist?
https://www.undervalued-shares.com/weekly-dispatches/alk-abello-denmarks-next-pharma-highflyer
